These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 1976046)

  • 1. Human debrisoquine hydroxylase gene polymorphisms in cancer patients and controls.
    Sugimura H; Caporaso NE; Shaw GL; Modali RV; Gonzalez FJ; Hoover RN; Resau JH; Trump BF; Weston A; Harris CC
    Carcinogenesis; 1990 Sep; 11(9):1527-30. PubMed ID: 1976046
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PCR-based CYP2D6 genotyping for Finnish lung cancer patients.
    Hirvonen A; Husgafvel-Pursiainen K; Anttila S; Karjalainen A; Pelkonen O; Vainio H
    Pharmacogenetics; 1993 Feb; 3(1):19-27. PubMed ID: 8097947
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of the CYP2D6 gene in relation to debrisoquin and desipramine hydroxylation in a Swedish population.
    Dahl ML; Johansson I; Palmertz MP; Ingelman-Sundberg M; Sjöqvist F
    Clin Pharmacol Ther; 1992 Jan; 51(1):12-7. PubMed ID: 1346258
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Xbal 16- plus 9-kilobase DNA restriction fragments identify a mutant allele for debrisoquin hydroxylase: report of a family study.
    Evans WE; Relling MV
    Mol Pharmacol; 1990 May; 37(5):639-42. PubMed ID: 1971090
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Debrisoquine oxidation polymorphism: phenotypic consequences of a 3-base-pair deletion in exon 5 of the CYP2D6 gene.
    Broly F; Meyer UA
    Pharmacogenetics; 1993 Jun; 3(3):123-30. PubMed ID: 8101460
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Two mutant alleles of the human cytochrome P-450db1 gene (P450C2D1) associated with genetically deficient metabolism of debrisoquine and other drugs.
    Skoda RC; Gonzalez FJ; Demierre A; Meyer UA
    Proc Natl Acad Sci U S A; 1988 Jul; 85(14):5240-3. PubMed ID: 2899325
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Frequent distribution of ultrarapid metabolizers of debrisoquine in an ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles.
    Aklillu E; Persson I; Bertilsson L; Johansson I; Rodrigues F; Ingelman-Sundberg M
    J Pharmacol Exp Ther; 1996 Jul; 278(1):441-6. PubMed ID: 8764380
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic cytochrome P450 genotypes and assessment of individual susceptibility to lung cancer.
    Hirvonen A; Husgafvel-Pursiainen K; Anttila S; Karjalainen A; Sorsa M; Vainio H
    Pharmacogenetics; 1992 Dec; 2(6):259-63. PubMed ID: 1306126
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quinidine inhibition of debrisoquine S(+)-4- and 7-hydroxylations in Chinese of different CYP2D6 genotypes.
    Bertilsson L; Meese CO; Yue QY; Dahl ML; Ingelman-Sundberg M; Johansson I; Säwe J; Eichelbaum M
    Pharmacogenetics; 1993 Apr; 3(2):94-100. PubMed ID: 8100167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis.
    Dahl ML; Johansson I; Bertilsson L; Ingelman-Sundberg M; Sjöqvist F
    J Pharmacol Exp Ther; 1995 Jul; 274(1):516-20. PubMed ID: 7616439
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population.
    Broly F; Gaedigk A; Heim M; Eichelbaum M; Morike K; Meyer UA
    DNA Cell Biol; 1991 Oct; 10(8):545-58. PubMed ID: 1681816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic and metabolic criteria for the assignment of debrisoquine 4-hydroxylation (cytochrome P4502D6) phenotypes.
    Daly AK; Armstrong M; Monkman SC; Idle ME; Idle JR
    Pharmacogenetics; 1991 Oct; 1(1):33-41. PubMed ID: 1688241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concordance of P450 2D6 (debrisoquine hydroxylase) phenotype and genotype: inability of dextromethorphan metabolic ratio to discriminate reliably heterozygous and homozygous extensive metabolizers.
    Evans WE; Relling MV
    Pharmacogenetics; 1991 Dec; 1(3):143-8. PubMed ID: 1688245
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human CYP2D6 gene polymorphism in Slovene cancer patients and healthy controls.
    Dolzan V; Rudolf Z; Breskvar K
    Carcinogenesis; 1995 Nov; 16(11):2675-8. PubMed ID: 7586185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ultrarapid metabolizers of debrisoquine: characterization and PCR-based detection of alleles with duplication of the CYP2D6 gene.
    Løvlie R; Daly AK; Molven A; Idle JR; Steen VM
    FEBS Lett; 1996 Aug; 392(1):30-4. PubMed ID: 8769309
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The debrisoquine metabolic phenotype and DNA-based assays: implications of misclassification for the association of lung cancer and the debrisoquine metabolic phenotype.
    Caporaso NE; Shields PG; Landi MT; Shaw GL; Tucker MA; Hoover R; Sugimura H; Weston A; Harris CC
    Environ Health Perspect; 1992 Nov; 98():101-5. PubMed ID: 1362537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular heterogeneity of the XbaI defined 44kb allele of the CYP2D locus within the Caucasian population.
    Mura C; Gerard N; Vincent-Viry M; Galteau MM; Jacqz-Aigrain E; Krishnamoorthy R
    Br J Clin Pharmacol; 1993 Feb; 35(2):161-5. PubMed ID: 8095148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutant genes of cytochrome P-450IID6, glutathione S-transferase class Mu, and arylamine N-acetyltransferase in lung cancer patients.
    Roots I; Brockmöller J; Drakoulis N; Loddenkemper R
    Clin Investig; 1992; 70(3-4):307-19. PubMed ID: 1355678
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of a novel CYP2D6 allele associated with poor metabolism of sparteine in a Japanese population.
    Kondo I; Yonaha M; Okano K; Gonzalez FJ; Kanazawa I
    Pharmacogenetics; 1991 Dec; 1(3):161-4. PubMed ID: 1688247
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation of polymorphic expression of CYP2D6 mRNA in bladder mucosa and tumor tissue to in vivo debrisoquine hydroxylase activity.
    Romkes-Sparks M; Mnuskin A; Chern HD; Persad R; Fleming C; Sibley GN; Smith P; Wilkinson GR; Branch RA
    Carcinogenesis; 1994 Sep; 15(9):1955-61. PubMed ID: 7923590
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.